Biovisus operates as an independent brand with full ownership of its optical technology, imaging algorithms, quality systems, and customer relationships. Governance is not a bureaucratic overlay—it is the framework that ensures every strategic decision, from optical architecture to market entry, serves one fixed reference point: diagnostic accuracy and patient safety.
Since its founding in 2016, Biovisus has maintained a lean but rigorous governance structure. Shareholders appoint a Board of Directors responsible for strategic oversight. The Board brings together expertise in gastroenterology, minimally invasive surgery, optical engineering, biomedical imaging, and global regulatory affairs—ensuring that product decisions are grounded in clinical reality, not commercial convenience.
Specialized committees operate within the Board, proportionate to the company’s scale:
Audit Committee — Oversees financial reporting, internal controls, and external audits. Financial integrity supports optical integrity.
Nomination Committee — Maintains the right mix of skills and independence on the Board, identifying members who understand endoscopic and microscopic diagnosis.
Compensation Committee — Aligns executive rewards with longterm value creation: system uptime, image fidelity, customer satisfaction, and patient safety.
The Board appoints executive officers to carry out the strategic vision. Internal groups support them, including a Clinical Imaging & Technology Committee that reviews optical performance, image processor latency, adverse event reports, and singleuse endoscope sterility validation, and a Risk & Compliance Panel that manages regulatory changes, supplier audits, and field corrections. An independent Internal Audit team reports directly to the Audit Committee.
Headquartered in Shenzhen, Biovisus applies these governance principles consistently across all markets. Lean structure does not mean weak governance—it means every decision is visible, every risk is owned, every leader is accessible.
Governance is not a chart. It is a covenant with the people who rely on Biovisus systems: patients awaiting accurate diagnosis, endoscopists interpreting every mucosal detail, surgeons performing minimally invasive procedures, pathologists examining tissue specimens, and hospital administrators managing finite resources.
Biovisus is guided by its founding team and an executive management group, with long‑term direction reviewed by a Board of Directors. The Board ensures that strategy—product development, optical technology planning, and market expansion—remains aligned with core values and patient safety.
A dedicated Clinical Imaging & Technology Committee oversees technical and clinical risk areas. It reviews optical‑resolution complaints, image‑processor field issues, single‑use sterility incidents, and regulatory inspection findings. The committee meets quarterly and reports directly to the Board, ensuring that quality and safety remain central rather than secondary to commercial goals.
Three anchors guide every decision: transparency, accountability, and a strict focus on diagnostic accuracy. Design reviews, optical supplier selection, field corrections, and post‑market surveillance are fully documented and auditable. Accountability extends to the endoscopists, surgeons, and pathologists who rely on every image and every optical parameter.
Biovisus operates under a certified quality management system compliant with ISO 13485, the global standard for medical device manufacturers. Risk management follows ISO 14971, with focus on electrical safety, photobiological safety, single‑use sterility validation, and optical radiation safety.
NMPA registration in China, CE marking under MDR for selected products, and other regional approvals are maintained directly by Biovisus. Regulatory changes in China, the EU, and other target markets are monitored continuously. Compliance is a daily discipline built on document control, training, and strict process adherence.
Because Biovisus vertically integrates its optical technology and manufacturing, the company maintains direct control over supplier qualification. Annual on‑site audits verify adherence to ISO 13485 and relevant endoscope and microscope standards. No optical component or assembly enters a Biovisus system without passing internal verification.
We view clinicians, hospital teams, engineers, distributors, regulators, employees, and manufacturing partners as essential stakeholders. Engagement is practical: clinical advisory boards during development, post‑installation surveys for every new site, open channels for distributors to report field issues, and regular quality reviews with factory partners. We are not a distant organization—we are accessible, and we listen, because listening drives meaningful improvement.
Subscribe to comprehensive endoscopic and minimally invasive solutions from Biovisus.Elevate diagnostic precision and therapeutic outcomes across GI, pulmonology, urology, and surgical suites with integrated imaging and procedural systems.
© Nortek HealthCare Group Ltd., 2009-2026. All rights reserved.
This site operates under the laws of the People's Republic of China. Your access and use constitute acceptance of these Terms of Use and our Privacy Policy. All content is governed by our Privacy Notice. For details or inquiries, please Contact Us or use the site's search function.
